EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa

Sophie E Müller iD, Sabryna Junker, Jacqueline Rehner, Maximilian Förster, Andreas Keller iD, Leidy-Alejandra G Molano, Sören L Becker iD

Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3352-3356

DOI: 10.1093/jac/dkaf376 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.10.2025. Verfasst von Sophie E Müller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Microbiology and Hygiene, Saarland University, Kirrberger Straße, Building 43, Homburg 66421, Germany. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Aztreonam, Ceftazidime, Azabicyclo Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives MDR Pseudomonas aeruginosa is difficult to treat, despite some new beta-lactam/beta-lactamase inhibitors. A combination of ceftazidime–avibactam and aztreonam (CAZ/AVI + AZT) is frequently used to treat Gram-negative bacteria expressing metallo-beta-lactamases. A fixed combination of aztreonam/avibactam was recently licenced for use in Europe, but it remains unknown whether there are differences between both options for use against P. aeruginosa. This study evaluates the comparative in vitro efficacy of the fixed combination aztreonam/avibactam compared to the three antibiotics CAZ/AVI + AZT against clinical MDR P. aeruginosa isolates.

Methods

MICs for aztreonam/avibactam and CAZ/AVI + AZT were determined in 38 MDR P. aeruginosa isolates recovered from routine diagnostics using broth microdilution with checkerboard assays in triplicates as the reference method. Fractional inhibitory concentration (FIC) indices were calculated. Whole-genome sequencing was performed on all isolates.

Results

At a fixed ceftazidime concentration of 8 mg/L (EUCAST breakpoint), 25 isolates exhibited lower MICs for CAZ/AVI + AZT compared to aztreonam/avibactam alone in microdilution assays. On FIC analysis, additive and synergistic effects were seen in 28 and 2 cases, respectively. Verona integron-encoded metallo-beta-lactamase (VIM) was the most prevalent carbapenemase (21/38 isolates), followed by Imipenemase (IMP, 4/38) and New Delhi metallo-beta-lactamase (NDM, 2/38). Lower MICs were observed for the combination CAZ/AVI + AZT in isolates carrying VIM-2 as compared to VIM-1.

Conclusions

In vitro testing of CAZ/AVI + AZT revealed increased in vitro susceptibility among MDR P. aeruginosa isolates in comparison to the fixed combination of aztreonam/avibactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAztreonamCeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsDrug Resistance, Multiple, Bacterialbeta-Lactamase InhibitorsMicrobial Sensitivity TestsHumansDrug CombinationsPseudomonas Infectionsbeta-Lactamases

Substanzen

AztreonamCeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationDrug CombinationsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-Lactamases

Autor:innen und Institutionen

  • Institute of Medical Microbiology and Hygiene, Saarland University, Kirrberger Straße, Building 43, Homburg 66421, Germany.
  • Clinical Bioinformatics, Saarland University, Saarbrücken 66123, Germany.
  • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University Campus, Saarbrücken, Germany.
  • PharmaScienceHub, Saarbrücken, Germany.

ORCID-Profile: Sophie E Müller, Andreas Keller, Sören L Becker

Förderung

  • Deutsche Forschungsgemeinschaft
  • European Union

Zitieren

APA

Müller, S. E., Junker, S., Rehner, J., Förster, M., Keller, A., Molano, L. G., & Becker, S. L. (2025). Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 80(12), 3352-3356. https://doi.org/10.1093/jac/dkaf376

Vancouver

Müller SE, Junker S, Rehner J, Förster M, Keller A, Molano LG, et al. Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 2025;80(12):3352-3356. doi:10.1093/jac/dkaf376

BibTeX
@article{Mller2025,
  author = {Müller, Sophie E and Junker, Sabryna and Rehner, Jacqueline and Förster, Maximilian and Keller, Andreas and Molano, Leidy-Alejandra G and Becker, Sören L},
  title = {Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {12},
  pages = {3352--3356},
  doi = {10.1093/jac/dkaf376}
}
Kostenlos starten →